Endpoints News is now 5 years old. Here's how you can support us for the next phase of growth
Endpoints News turned five years old over the weekend. I wanted to mark the happy occasion by extending our deepest gratitude to Endpoints’ premium subscribers while outlining several other ways to support us as we go broader and get bigger this year and beyond.
Same as any business, we’ve got to create value and get paid for delivering it. So if you depend on Endpoints to stay abreast on biopharma developments, we depend on you too.
The best way to support us is by upgrading to a premium subscription. It’s our most important source of revenue because it ties our editorial incentives directly to reader expectations — focusing on quality over quantity. We work to deliver something worth paying for every day. Not just another email clogging your inbox.
We have two plans: Insider for individuals ($225/year) and Enterprise for companies ($1,000/year). Both of them unlock the complete Endpoints experience and content library. The Enterprise plan is a flat rate that covers all employees, and you don’t need to negotiate rates with us or pick who on your team gets access. Everyone does. Check out our entire premium catalog here.
And if you have questions, our customer service team is quick to respond — you can chat with them.
This year we launched three new titles. Endpoints FDA+ and Endpoints Manufacturing — spearheaded by senior editor Zachary Brennan and managing editor Kyle Blankenship, respectively — is your one-stop look at the most critical developments in those fields and what they mean for biopharma. And senior editor Amber Tong is behind our new Endpoints Weekly, which recaps the busy week in biopharma every Saturday morning. You can add these titles to your subscription by visiting your Reader Profile, or if you’re new to Endpoints, via our sign-up page.
If a premium subscription isn’t in the cards yet, but you’d still like to support us, please help spread the word and share Endpoints with your collaborators. Nothing is better than referrals, and it’s where we get most of our new subscribers. Just share our URLs and forward our email reports to your colleagues. Most Endpoints coverage is free to read, with no payment required for a basic subscription.
We’ve also spent the past five years optimizing our advertising products. So for marketing leaders who need to reach either a large or targeted audience in the life sciences, we’d love to talk.
Endpoints is different in that we intentionally keep advertising space tight. That helps pop the brand advertising campaigns on our site. It reduces sponsorship fatigue from the readers and increases conversions. Our chief revenue officer Mike Peck has built a sales team where relationships matter most. We’re interested in getting more from clients who see excellent results with us, not milking every deal for pennies. And Endpoints’ customer service, led by our talented COO Shelly Whitfield, is second-to-none. Her team works to execute campaigns for 200+ advertising clients, and they do great work.
After five years in business, we’ve grown to 32 full-time employees with more on the way. 100,000+ industry pros get our news directly in their inbox daily. During the pandemic, our virtual events attracted 32,000 attendees. And yet, Endpoints’ mission hasn’t changed since day one: Inform and connect the biopharma world with relentless daily reporting.
To all of our current premium subscribers who’ve directly funded our growth: Thank you. Getting to this milestone was impossible without your support. To everyone who is considering getting one today for themselves or their company: We’ll work hard to continue earning your support every day.